Drugs / BT02
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07107178 | Aug 2025 → May 2027 expected | melanoma | Biotroy Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07110363 | Aug 2025 → Mar 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | Biotroy Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06404905 | Jan → Dec 2024 overdue | neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07107204 | Oct 2025 → Jan 2028 expected | leukemia, plasma cell myeloma, refractory hematologic cancer | Biotroy Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07107204 ↗ |
| Modality | Monoclonal antibody | “BT02 monoclonal antibody injection” NCT06404905 ↗ |
| Route | Intravenous | “BT02 given intravenously administer in patients with advanced solid tumors.” NCT06404905 ↗ |